Watson CEO alleges FTC shared confidential info in attempt to broker deal for generic Provigil
This article was originally published in Scrip
An unusual court fight is ongoing between the CEO of Watson Pharmaceuticals, Paul Bisaro, and the US Federal Trade Commission. Mr Bisaro has alleged that the FTC shared confidential information with a competitor, Apotex, and improperly attempted to broker a business deal between the two generic drug makers for the genericisation of the US market for Cephalon's sleep disorder drug Provigil (modafinil), all the while undercutting a reverse-payment settlement that Watson and other generics firms made with Cephalon in 2005. Mr Bisaro also claims that the FTC is improperly attempting to subpoena him.